# Somatic Gene Therapy vs. Germline Editing: Where to Draw the Line

## Introduction

The distinction between somatic gene therapy (modifying non-reproductive cells of an affected individual) and germline editing (modifying reproductive cells or embryos such that changes are inherited by future generations) represents one of the most consequential ethical boundaries in modern medicine. While somatic gene therapy has progressed to multiple approved treatments, germline editing remains highly controversial and is subject to widespread moratoriums.

## Somatic Gene Therapy: The Current Paradigm

### Definition and Scope

Somatic gene therapy involves genetic modification of non-germline cells in a living individual. The changes are confined to the treated individual and are not heritable, making the approach conceptually analogous to other medical interventions where benefits and risks accrue to the patient alone. It encompasses gene addition, gene editing, gene silencing, and gene regulation in somatic tissues.

### Ethical Justification

Somatic gene therapy falls within established frameworks of medical beneficence and informed consent. The patient or legal guardian can consent to personal risk for personal benefit, and risks are bounded because any adverse effect affects only the treated individual. Regulatory oversight follows standard drug and biologic approval pathways through agencies such as the FDA and EMA. Ethical debates in somatic gene therapy center on practical issues including safety, efficacy, access, cost, and long-term monitoring rather than fundamental questions about the permissibility of the approach itself.

### Current Clinical Landscape

Multiple FDA-approved somatic gene therapies are now in clinical use (see Lecture 72), with active clinical trials spanning hundreds of genetic conditions. Delivery strategies include both ex vivo approaches (targeting hematopoietic stem cells or T cells) and in vivo approaches (targeting the liver, retina, CNS, or muscle). Gene editing via CRISPR in somatic cells, exemplified by exa-cel for sickle cell disease, has been approved and is in practice.

![Diagram contrasting somatic gene therapy and germline editing showing which cells are modified and whether changes are heritable](images/somatic-vs-germline.png)

## Germline Editing: The Controversy

### Definition

Germline editing involves genetic modification of gametes (sperm or eggs), zygotes, or early embryos such that the changes are incorporated into every cell of the resulting organism, including future reproductive cells. This means changes are transmitted to all future descendants, and no individual can consent on behalf of future generations.

### The He Jiankui Case (2018)

In 2018, Chinese researcher He Jiankui used CRISPR-Cas9 to edit embryos, targeting the CCR5 gene (an HIV co-receptor) in an attempt to confer HIV resistance. Two girls were born from edited embryos, and a third pregnancy followed. The scientific community and regulatory authorities condemned the work on multiple grounds. There was a lack of medical necessity, since PrEP and other interventions effectively prevent HIV transmission. Informed consent was inadequate, as the parents were not adequately informed of the risks. The science was premature because off-target effects were not adequately characterized. The work bypassed institutional and national review, occurring in the absence of regulatory oversight. Additionally, editing was incomplete, creating mosaicism with some cells carrying the intended edit and others not. He Jiankui was sentenced to prison in China, and the case catalyzed global calls for governance frameworks.

### Scientific Concerns

Off-target editing can produce unintended modifications elsewhere in the genome that are potentially oncogenic and would be inherited by all descendants. Mosaicism from incomplete editing creates individuals with mixed cell populations, undermining therapeutic intent. Pleiotropy poses a challenge because many genes have multiple functions, so disrupting one function (such as CCR5 for HIV resistance) may impair another (such as susceptibility to West Nile virus). For most genetic conditions, preimplantation genetic testing (PGT) can identify unaffected embryos, making germline editing unnecessary. Unknown long-term effects are also a concern, as epigenetic consequences and effects on gene regulation across generations remain unpredictable.

## Ethical Arguments

### Against Germline Editing

The argument from consent holds that future generations cannot consent to modifications that will permanently affect their genome. Eugenics concerns arise because germline modification could lead to selection for non-medical traits, exacerbating inequality. The slippery slope argument suggests that therapeutic use may open the door to non-therapeutic enhancement. Irreversibility is a critical issue because once a germline edit propagates through a population, it cannot be recalled. Social justice considerations highlight that access to germline editing would likely be restricted to the wealthy, creating genetic inequities. Disability rights advocates argue that the drive to eliminate genetic conditions may devalue the lives of people living with those conditions. Finally, alternatives already exist in the form of PGT-M, prenatal diagnosis, and adoption for families concerned about transmitting genetic conditions.

### In Favor of (Carefully Regulated) Germline Editing

Medical necessity arguments point to rare scenarios where both parents are homozygous for a recessive condition (for example, both parents having cystic fibrosis) and all embryos would be affected. For devastating conditions with no effective treatment, the severity of disease may justify the potential risk. Some invoke reproductive autonomy, arguing that families should have the right to use available technology to prevent serious genetic disease. A scientific consistency argument observes that if somatic gene editing is acceptable, the distinction between modifying cells that happen to be in the germline versus other cells may be considered arbitrary. The possibility of eradicating severe alleles by permanently removing devastating disease-causing variants from the gene pool could eliminate suffering for future generations.

![Ethical framework diagram showing the spectrum from clearly permissible somatic therapy through debated reproductive applications to widely prohibited enhancement](images/germline-ethics-spectrum.png)

## Professional and Regulatory Positions

### International Consensus

The WHO Expert Advisory Committee on Governance of Human Genome Editing published a governance framework in 2021, recommending against clinical application of heritable genome editing until safety and efficacy criteria are met and calling for national and international oversight mechanisms. The National Academies of Sciences concluded in 2017 that germline editing should only be permitted for compelling medical reasons under strict oversight with no reasonable alternative, emphasizing that enhancement should not be permitted. The International Commission on the Clinical Use of Human Germline Genome Editing concluded in 2020 that the science is not yet ready for clinical use and defined a translational pathway with stringent criteria.

### Regulatory Status

In the United States, the Dickey-Wicker Amendment prohibits federal funding for research involving human embryo destruction, the FDA has stated it will not accept clinical trial applications for germline editing, and Congressional riders prohibit the FDA from reviewing such applications. In the United Kingdom, the Human Fertilisation and Embryology Authority (HFEA) regulates embryo research and germline modification for reproduction is currently prohibited, though mitochondrial replacement therapy, a form of germline modification, was approved in 2015. China enacted regulations after the He Jiankui case requiring government approval for gene-editing research in humans, with criminal penalties for unauthorized germline editing. Most countries have laws, regulations, or guidelines prohibiting or restricting clinical germline editing, while a minority have no specific legislation.

| Feature | Somatic Gene Therapy | Germline Editing |
|---|---|---|
| Target cells | Non-reproductive (somatic) cells | Gametes, zygotes, or early embryos |
| Heritability | Not heritable; confined to treated individual | Heritable; passed to all future descendants |
| Consent | Patient/guardian can consent | Future generations cannot consent |
| Regulatory status | Multiple approved therapies (FDA, EMA) | Clinical application prohibited or under moratorium in most countries |
| Alternatives | Standard medical treatments | PGT-M, prenatal diagnosis, donor gametes |
| Reversibility | Effects confined to individual's lifespan | Irreversible once propagated in population |
| Current ethical consensus | Broadly accepted with standard oversight | No consensus for clinical use; moratorium widely supported |
| Example | Exa-cel for sickle cell disease | He Jiankui CCR5 editing (condemned) |

## Mitochondrial Replacement Therapy: A Special Case

Mitochondrial replacement therapy (MRT) involves replacing disease-causing mitochondrial DNA by transferring nuclear DNA to an enucleated donor oocyte with healthy mitochondria. This is technically a form of germline modification because the mitochondrial DNA change is heritable. MRT was approved in the UK in 2015 but has not been approved by the FDA in the United States. The procedure involves three genetic contributors (nuclear DNA from both parents and mitochondrial DNA from a donor), and it raises important questions about the boundaries between somatic and germline modification.

## The Path Forward

Research on human embryos is permitted in some jurisdictions under strict oversight, with the 14-day rule typically governing embryo culture duration. Extensive preclinical evidence of safety and efficacy would be required before any clinical translation of germline editing. Coordinated international governance is needed to prevent regulatory arbitrage, where procedures might be performed in less regulated jurisdictions. Broad societal dialogue through public engagement about the values and boundaries of human genome modification is essential. Most professional bodies currently support an ongoing moratorium on clinical germline editing until safety, efficacy, and governance criteria are met.

![Governance framework diagram showing the pathway from basic research through preclinical development, regulatory review, and societal deliberation for human germline editing](images/germline-governance-pathway.png)

## Clinical Pearls

Somatic gene therapy modifies only the treated individual and follows established ethical and regulatory frameworks, making it the appropriate and accepted approach for gene therapy in clinical practice. Germline editing would alter the genome of all future descendants and currently lacks the scientific certainty and ethical consensus required for clinical application. For the vast majority of genetic conditions, preimplantation genetic testing provides a viable alternative to germline editing for families seeking to avoid transmitting a known pathogenic variant. Clinical geneticists should be prepared to discuss the distinction between somatic and germline approaches with patients who may have questions prompted by media coverage of CRISPR and gene editing.

## References

1. National Academies of Sciences, Engineering, and Medicine. *Human Genome Editing: Science, Ethics, and Governance*. Washington, DC: The National Academies Press; 2017.
2. Lander ES, Baylis F, Zhang F, et al. Adopt a moratorium on heritable genome editing. *Nature*. 2019;567(7747):165-168.
3. World Health Organization. *Human Genome Editing: Recommendations*. Geneva: WHO; 2021.
4. Musunuru K, Lagor WR, Bhatt DL. CRISPR and cardiovascular diseases. *Circulation Research*. 2023;132(1):8-30.